UNSPSC 51171614: Bisacodyl

This classification denotes a laxative with the molecular formula C22H19NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10X0709Y6I, chemically known as 4,4-diacetoxydiphenylpyridyl-2-methane but generally known as bisacodyl, which bears US NIH Compound Identifier 2391. Bisacodyl most often comes in base and tannex forms. European Medicines Agency schedules Bisacodyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05846MIG.

UNSPSC 51171614 Bisacodyl is a Commodity code representing individual pharmaceutical products that state and local procurement offices purchase as part of broader pharmaceutical supply contracts and correctional healthcare programs. The recent opportunities tagged to this code show state and local governments buying bisacodyl primarily through two channels: as a component of multi-source generic pharmaceutical cooperative purchasing agreements serving multiple state and local facilities, and as part of specimen collection and drug testing service contracts that include pharmacy-adjacent services. The issuing bodies include state health departments, cooperative purchasing alliances serving multiple states and municipalities, and county correctional supervision agencies. Scope of work ranges from supplying individual pharmaceutical SKUs with specific NDC codes and dosage forms through authorized wholesaler networks to supporting drug screening and confirmatory testing programs that may include ancillary pharmaceutical services.

Recent activity centers in Texas and Minnesota, with broader participation through multi-state cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with responses due March 26, 2026, serving state and local facilities across Minnesota and Oregon; MMCAP reserves award discretion across sole, dual, or multiple vendors and weights price competitiveness at 75 percent of evaluation. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) exploring direct-to-manufacturer prescription programs for the state's pharmacy benefit system, though this represents exploratory market research rather than a binding procurement. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and term through September 1, 2026, reflects collateral pharmaceutical purchasing within correctional healthcare contexts. The code shows modest but active recent solicitation across state health agencies and cooperative purchasing entities, with evaluation criteria emphasizing price, compliance certifications (cGMP, DSCSA, SAMHSA), and wholesaler integration.